We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Hyperthermic Treatment with Carbon Nanotubes Kills Breast Cancer Stem Cells

By LabMedica International staff writers
Posted on 01 Mar 2012
Hyperthermic treatment of breast tumors with multiwall carbon nanotubes (MWCNTs) has been found to kill both differentiated cancer cells and the breast cancer-stem cells that drive tumor growth and recurrence.

Breast tumors contain a small population of tumor initiating stem-like cells, termed breast cancer-stem cells (BCSCs). More...
These cells, which are refractory to chemotherapy and radiotherapy, are thought to persist following treatment and drive tumor recurrence.

Having successfully used MWCNTs to treat breast tumors in a mouse model, investigators at Wake Forest Baptist Medical Center (Winston-Salem, NC, USA) examined their effect on. To this end, they worked with a mouse breast-cancer model. Tumors containing BCSCs were injected with nanotubes, which were then exposed to laser-generated, near-infrared radiation. The nanotubes vibrated, creating local areas of high temperature.

Results published in the April 2012 online edition of the journal Biomaterials revealed that that despite being markedly resistant to traditional hyperthermia BCSCs were sensitive to nanotube-mediated thermal treatment and lost their long-term proliferative capacity. Moreover, use of this therapy in vivo promoted complete tumor regression and long-term survival of mice bearing cancer stem cell-driven breast tumors.

The investigators speculated that nanotube thermal therapy promoted rapid membrane permeabilization and necrosis of the BCSCs. Destruction of the BCSCs prevented recurrence of the tumor.

“They are tough. These are cells that do not divide very often. They just sort of sit there, but when they receive some sort of trigger – and that is not really well understood – it is believed they can migrate to other sites and start a metastasis somewhere else,” said senior author Dr. Suzy Torti, professor of biochemistry at Wake Forest Baptist Medical Center. “Heat-based cancer treatments represent a promising approach for the clinical management of cancers, including breast cancer.”

“To truly cure a cancer, you have to get rid of the entire tumor, including the small population of cancer stem cells that could give rise to metastasis,” said Dr. Torti. “There is more research to be done. We are looking at five to 10 years of more study and development. But what this study shows is that all that effort may be worth it – it gives us a direction to go for a cure.”

Related Links:

Wake Forest Baptist Medical Center




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.